Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference

Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) announced participation in two investor conferences in May 2022. The H.C. Wainwright Global Investment Conference will be held from May 23-26 in Miami, Florida, with a presentation scheduled for May 24 at 7am ET. Meanwhile, the Equity Forum German Spring Conference takes place from May 23-25 in Frankfurt, Germany, featuring a presentation at 8:30am CET on May 24. The company is known for its ColoAlert test for early colorectal cancer detection, which is CE-IVD marked and expanding into the U.S. market.

BERKELEY, Calif. and MAINZ, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable investor conferences in May, 2022, the H.C. Wainwright Global Investment Conference and the Equity Forum German Spring Conference.

H.C. Wainwright Global Investment Conference

Date: May 23-26, 2022
Location: Miami, Florida
Presentation: 7am ET, May 24, 2022

The H.C. Wainwright Global Investment Conference combines leading industry keynote speakers and presenting companies with investor one-on-one meetings and networking events.

To register for the event, please visit https://hcwevents.com/globalconference/.

Equity Forum German Spring Conference

Date: May 23-25, 2022
Location: Frankfurt, Germany
Presentation: 8:30am CET, Tuesday, May 24, 2022 - Conference Room II

The spring conference is a MiFiD II compliant event with over 100 listed companies taking part in corporate presentations, one-on-one meetings and networking events with investors, analysts, financial journalists, intermediaries and financial industry experts.

To register for the event, please visit https://equityforum.de/en/german-spring-conference

About ColoAlert
ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the European Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
*Dollinger MM et al. (2018)

About the ColoFuture Study
The ColoFuture study is an international clinical trial evaluating over 600 patients (women or men) in the age range of 40-85 at two participating centers in Norway and two in Germany. Subjects are invited to potentially participate in the trial when referred for a colonoscopy (pre-inclusion) to screen for CRC or an overall diagnostic analysis. Those who agree to provide a stool sample in advance of the procedure will be eligible for participation. Inclusion criteria are based on one of the following diagnostic outcomes: CRC, advanced precancerous lesions in colon, or normal colon. Then, each patient outcome will compare the observations recorded from the colonoscopy to the results from the ColoAlert test that incorporates the novel biomarkers. The primary endpoints of the study are to determine sensitivity and specificity rates for CRC with ColoAlert plus the new mRNA biomarkers. There are multiple secondary endpoints for evaluating the modified ColoAlert test, including, determining sensitivity for AA lesions in colon, specificity for advanced precancerous lesions in colon and, specificity for no colorectal finding (normal colon). The Company is expecting to complete enrollment during the second half of 2022 and is targeting reporting study results in early 2023.

About Colorectal Cancer
Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the U.S. should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these U.S.-based 50+ populations every three years as prescribed equates to a U.S. market opportunity of approximately $3.7 Billion per year.

About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

For more information, please visit www.mainzbiomed.com

For media enquiries, please contact press@mainzbiomed.com

For investor enquiries, please contact ir@mainzbiomed.com

Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its registration statement on Form F-1 filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

 

FAQ

What is the stock symbol for Mainz Biomed?

The stock symbol for Mainz Biomed is MYNZ.

When is the H.C. Wainwright Global Investment Conference?

The H.C. Wainwright Global Investment Conference is from May 23-26, 2022.

What date and time will Mainz Biomed present at the H.C. Wainwright Global Investment Conference?

Mainz Biomed will present at 7am ET on May 24, 2022.

When is the Equity Forum German Spring Conference?

The Equity Forum German Spring Conference is from May 23-25, 2022.

What time will Mainz Biomed present at the Equity Forum German Spring Conference?

Mainz Biomed's presentation is scheduled for 8:30am CET on May 24, 2022.

What is ColoAlert and its significance?

ColoAlert is a test developed by Mainz Biomed for the early detection of colorectal cancer, known for its high sensitivity and specificity.

What market opportunity does Mainz Biomed have in the U.S.?

Mainz Biomed targets a U.S. market opportunity of approximately $3.7 billion annually for colorectal cancer screening.